DB-3Q for treatment-resistant Crohn's disease
Part of Digestive system clinical trials.
This trial tests a new medicine called DB-3Q for people with Crohn's disease that hasn't responded to standard biologic treatments or causes side effects. The study aims to see if DB-3Q can reduce inflammation and symptoms in people whose disease is hard to control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 with Crohn's disease lasting at least 6 months
- Active disease confirmed by test scores (CDAI ≥220 or SES-CD ≥4) and failure of at least one advanced immunologic therapy (like adalimumab, infliximab, or vedolizumab) given for at least 14 weeks
- Recent colonoscopy (within 90 days) showing no cancer or precancerous cells
- Stable doses of certain Crohn's medicines for 2–4 weeks before treatment starts, with washout periods for recent biologic drugs (8 weeks) and JAK inhibitors (4 weeks)
- Normal or near-normal blood counts, liver and kidney function, and blood clotting tests at screening
- Willing to use birth control if of childbearing age
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This trial compares two different ways to choose your Crohn's treatment: one based on a special test of your cells (epigenetic markers) and the other based on standard care. It aims to see which approach works better for people with moderate to severe Crohn's disease.
This trial tests an experimental drug called R-3750 for people with active Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.